Out-of-pocket pricing for weight-loss medication

Some insurance plans cover weight loss medication, with copays as low as $25. Prices below reflect out-of-pocket costs. If prescribed, our insurance advocacy team will work to get you coverage whenever possible.
$25 average copay for weight management visits
16% average 12-month weight loss using  GLP-1s
Virtual & in-person visits with the same clinician

Explore Wegovy® pricing

Wegovy® Pill clinical trials showed
~14% average weight loss, 76% lost more than 5% of body weight
Wegovy® Pen clinical trials showed
~21% average weight loss at highest dose, 86% lost more than 5% of body weight.

Wegovy Pen

Weekly injection
GLP-1
Wegovy® Pill clinical trials showed
~14% average weight loss, 76% lost more than 5% of body weight

Wegovy Pill

Daily pill
GLP-1
Wegovy® Pen clinical trials showed
~21% average weight loss at highest dose, 86% lost more than 5% of body weight.

See if medication is right for you

knownwell visits covered by insurance
97% of knownwell patients keep weight off after two years
Virtual & in-person visits, with the same clinician

Explore Zepbound® pricing

Zepbound® clinical trials showed
~21% average weight loss, 91% lost more than 5% of body weight

Zepbound QwikPen

Weekly injection
GLP-1

Zepbound Vial

Weekly injection
GLP-1

Zepboun Pen

Weekly injection
GLP-1

Ozempic® pricing

Ozempic® clinical trials
~5 - 6% average weight loss, ~50% lost more than 5% of body weight

Ozempic Pen

Weekly injection
GLP-1
Diabetes medication

See if medication is right for you

Saxenda® pricing

Saxenda Pen

Daily injection
GLP-1
Saxenda® clinical trials showed
~8% average weight loss, 62% lost 5% or more of body weight

Foundayo® pricing

Foundayo Pill

Daily pill
GLP-1
Foundayo® clinical trials showed
~12% average weight loss, 55% lost more than 10% of body weight

Compare Contrave® & generic pricing

Contrave® clinical trials showed
~6% average weight loss, 48% lost more than 5% of body weight
*Contrave® clinical trials used a proprietary extended-release formulation and may not reflect results with generic naltrexone & bupropion taken separately.

Contrave Pill

Daily pill
Non GLP-1

Naltrexone & Bupropion*

Daily pill
Non GLP-1

Qsymia Pill

Daily pill
Non GLP-1

Phentermine & Topiramate*

Daily pill
Non GLP-1

Compare Qsymia® & generic pricing

Qsymia®  clinical trials showed
~10% average weight loss, 70% lost more than 5% of body weight
*Qsymia® clinical trials used a proprietary formulation and may not reflect results with generic phentermine & topiramate taken separately.

Get bias-free weight management with knownwell

World-class experts in weight management

Board-certified in Obesity Medicine (ABOM) clinicians who are up-to-date on the latest research in weight care.

Care that leads with empathy and your goals

Our care team takes the time to truly understand your history, your goals, and what matters most to you.

Access to weight management medication

GLP-1s and other FDA-approved obesity management medications — with monitoring and ongoing support every step of the way.

Longer visits, more complete care

First appointments are 40-minutes. Follow-ups are 20-minutes. See the same clinician so you don’t have to start over at every visit.

Choosing the right option with confidence

When choosing a weight-management medication, clinicians look at several key factors:
Looking at your overall health picture

Conditions like diabetes, cardiovascular disease, high blood pressure, migraines, or mood disorders influence which options are safest, most effective, and least likely to interact with existing health issues or medications.

Thinking about your health goals

Clinicians look at a patient’s target weight-loss percentage. Different treatments produce different average results, so goals such as achieving around 5–10%, 10–15%, or 15%+ total body weight reduction help guide which category of therapy is most appropriate.

Making sure it fits your budget

Prices vary widely among treatment types, and insurance coverage, cash-pay programs, and manufacturer savings offers can dramatically change out-of-pocket costs. Many patients ultimately choose a medication based on realistic long-term affordability.

Considering how your body may react

Each medication category comes with its own pattern of common side effects. Some treatments are more likely to cause gastrointestinal symptoms, while others may lead to things like tingling sensations, dry mouth, changes in mood, sleep disturbances, or blood pressure changes. Matching a patient’s tolerance and sensitivities to the expected side-effect profile is essential.

Finding what works best for your lifestyle

Some people prefer injectable treatments while others want oral daily medications. Others base their choice on whether they want stronger appetite suppression, more craving control, or a specific dosing schedule. Aligning the treatment to a patient’s lifestyle and comfort level helps support long-term success.

Disclaimers

knownwell does not dispense medications and is not a pharmacy. We do not set or control medication prices, and we do not receive any financial benefit based on which medication you choose, or whether you choose to use medication at all. Our role is to provide evidence-based medical guidance and help you access the safest, most effective treatment options for your care.

This page provides a centralized overview of obesity medication cash-pay drug pricing, based on information provided by the relevant drug manufacturer, to help you navigate treatment options, compare therapies, and stay informed throughout your care journey.

All pricing is list pricing based on information provided by the respective drug manufacturers. End user pricing may vary and for more details, consult with the drug manufacturers directly.

Sources

1.
Wilding, J. P. H.,Batterham, R. L.,Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity.New England Journal of Medicine, 384(11), 989-1002. doi:10.1056/NEJMoa2032183. Retrieved fromhttps://www.nejm.org/doi/full/10.1056/NEJMoa2 032183
2.
Wharton, S., Freitas, P.,Hjelmesæth, J., et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): arandomised, controlled, phase 3b trial.The LancetDiabetes & Endocrinology, 13(11), 949-963. doi:10.1016/S2213-8587(25)00226-8. Retrieved fromhttps://www.thelancet.com/journals/lan dia/article/PIIS2213-8587(25)0226-8/abstract
3.
Wharton, S.,Lingvay, I., Bogdanski, P., et al. (2025). Oral semaglutide at a dose of25 mgin adults with overweight or obesity.New England Journal of Medicine, 393(11), 1077-1087. doi:10.1056/NEJMoa2500969. Retrieved fromhttps://www.nejm.org/doi/full/10.1 056/NEJMoa2500969
See all
4.
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. doi:10.1056/NEJMoa2206038. Retrieved from https://www.nejm.org/doi/full/10.1 056/NEJMoa2206038
5.
Sorli, C., Harashima, S., Tsoukas, G. M., et al. (2017). Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The Lancet Diabetes & Endocrinology, 5(4), 251-260. doi:10.1016/S2213-8587(17)30013-X. Retrieved from https://pubmed.ncbi.nlm.nih.gov/28110911/
6.
Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22. doi:10.1056/NEJMoa1411892. Retrieved from https://www.nejm.org/doi/full/10.10 56/NEJMoa1411892
7.
Wharton, S., Aronne, L. J., Stefanski, A., et al. (2025). Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. New England Journal of Medicine, 393(18), 1796-1806. doi:10.1056/NEJMoa2511774. Retrieved from https://www.nejm.org/doi/full/10.1 056/NEJMoa2511774
8.
Greenway, F. L., Fujioka, K., Plodkowski, R. A., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595-605. doi:10.1016/S0140-6736(10)60888-4. Retrieved from https://pubmed.ncbi.nlm.nih.gov/20673995/
9.
Gadde, K. M., Allison, D. B., Ryan, D. H., et al. (2011). Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. The Lancet, 377(9774), 1341-1352. doi:10.1016/S0140-6736(11)60205-5. Retrieved from https://pubmed.ncbi.nlm.nih.gov/21481449/